Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...
In a recent transaction involving Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Mark Jeffrey DeLong, the company's Chief Business & Strategy Officer, sold 365 shares of common stock. The shares were ...
In 2024, the Summers Value Fund LP (“the Fund”) delivered a net1 return of 27.4%. Click here to read the full letter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback